发明名称 |
Immunosuppression compound and treatment method |
摘要 |
A method and compound for suppressing an immune response in a mammalian subject, for the treatment or prevention of an autoimmune condition or transplantation rejection are disclosed. The compound is an antisense oligonucleotide analog compound having a targeting sequence complementary to a preprocessed CTLA-4 mRNA region identified by SEQ ID NO: 22 in SEQ ID NO: 1, spanning the splice junction between intron 1 and exon 2 of the preprocessed mRNA of the subject. The compound is effective, when administered to a subject, to form within host cells, a heteroduplex structure (i) composed of the preprocessed CTLA-4 mRNA and the oligonucleotide compound, (ii) characterized by a Tm of dissociation of at least 45° C., and (iii) resulting in an increased ratio of processed mRNA encoding ligand-independent CTLA-4 to processed mRNA encoding full-length CTLA-4. |
申请公布号 |
US9487786(B2) |
申请公布日期 |
2016.11.08 |
申请号 |
US201414581485 |
申请日期 |
2014.12.23 |
申请人 |
SAREPTA THERAPEUTICS, INC. |
发明人 |
Mourich Dan V.;Iversen Patrick L.;Weller Dwight D. |
分类号 |
C12N15/11;A61K48/00;C07H21/02;C07H21/04;C12N15/113 |
主分类号 |
C12N15/11 |
代理机构 |
Seed IP Law Group LLP |
代理人 |
Seed IP Law Group LLP |
主权项 |
1. A phosphorodiamidate morpholino antisense oligonucleotide of 12 to 40 bases comprising a base sequence that is 100% complementary to contiguous bases of human CTLA-4 pre-mRNA, wherein the base sequence comprises at least 12 contiguous bases that are 100 complementary to SEQ ID NO: 22, and wherein the phosphorodiamidate morpholino antisense oligonucleotide induces skipping of exon 2 of the human CTLA-4 pre-mRNA. |
地址 |
Corvallis OR US |